Program Description: Lymph node metastases are clinically evident in papillary thyroid carcinoma in approximately 20% of cases, but occult metastases are present in 50% to 80%. Prophylactic node dissection may upstage a large proportion of patients over age 45. Recent work within the American Thyroid Association Surgical Affairs Committee with representation from the AAO-HNS Endocrine Committee has defined micrometastasis as <0.2 cm and has demonstrated that clinically N0 but pathologically N1 disease has a similar low rate of recurrence (3 cm, those with extracapsular spread, or multiple positive nodes are all associated with worse prognosis). Until summary TNM staging systems go beyond simply N0 and N1, clinicians should consider clinical nodal stage a better prognosticator than pathological. This miniseminar will review the evidence and present optimal management of the clinically N0 and N1 necks in papillary thyroid cancer. Focus will be on initial management, but recurrent disease will also be addressed. The panel will include an endocrine thyroid specialist and recognized experts in thyroid cancer.
Educational Objectives: 1) Describe the risk of recurrence of papillary thyroid cancer as a function of clinical and pathological nodal stage. 2) Describe optimal initial management of clinically node negative and node positive papillary thyroid carcinoma. 3) Understand risks and benefits of secondary nodal surgery for recurrent/persistent papillary thyroid carcinoma.
Management of Salivary Gland Malignancies: Update 2012
Kelly M. Malloy, MD (moderator); Stephen Y. Lai, MD; Daniel G. Deschler, MD; Richard J. Wong, MD; Patrick K. Ha, MD Program Description: While not commonly encountered, salivary gland malignancies can be a challenging problem for the otolaryngologist-head and neck surgeon. Salivary gland malignancies may be identified during work-up, but may also be discovered during surgery for presumed benign disease. The next best step in management may not be obvious. Consideration of additional surgery, elective neck dissection, and/or adjuvant radiation treatment is required. Management of the facial nerve remains challenging, especially with regard to facial nerve monitoring, intraoperative considerations related to sacrifice of the nerve, and overall reconstruction/rehabilitation. Even a benign pleomorphic adenoma can behave malignantly, as in the case of multiply recurrent benign mixed tumor or carcinoma ex pleomorphic adenoma. This miniseminar will gather expert surgeons for discussion of these important issues regarding management of salivary gland malignancies, and the approach to counseling patients regarding these difficult topics will be specifically addressed. The best available evidence will be presented to support the approaches to this diverse group of malignancies. Difficult clinical cases will be presented for audience and panel discussion regarding current management strategies.
Educational Objectives: 1) Understand the latest developments in the treatment of salivary gland malignancies. 2) Manage complicated situations such as an unexpected malignancy, an involved facial nerve, and other issues of reconstruction and function. 3) Evaluate the utility of facial nerve monitoring during parotid surgery.
